(Q38443780)

3 September 2017

title

Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge (English)

1 reference

3 September 2017

3

Emma Allen-Vercoe

1 reference

3 September 2017

Julia Vipond

1

1 reference

3 September 2017

Richard Vipond

2

1 reference

3 September 2017

Simon O Clark

4

1 reference

3 September 2017

Graham J Hatch

5

1 reference

3 September 2017

Karen E Gooch

6

1 reference

3 September 2017

Joanna Bacon

7

1 reference

3 September 2017

Toby Hampshire

8

1 reference

3 September 2017

Helen Shuttleworth

9

1 reference

3 September 2017

Nigel P Minton

10

1 reference

3 September 2017

Karen Blake

11

1 reference

3 September 2017

Ann Williams

12

1 reference

3 September 2017

Philip D Marsh

13

1 reference

3 September 2017

language of work or name

English

0 references

publication date

5 June 2006

1 reference

3 September 2017

1 reference

3 September 2017

volume

24

1 reference

3 September 2017

issue

37-39

1 reference

3 September 2017

page(s)

6340-6350

1 reference

TB subunit vaccines--putting the pieces together

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Variation in protection by BCG: implications of and for heterologous immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Recent progress in the development and testing of vaccines against human tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

The tuberculosis vaccine challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

NIH pre-clinical screening program: overview and current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

DNA vaccine strategies: candidates for immune modulation and immunization regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Vaccination against tuberculosis by DNA injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Immunogenicity and protective efficacy of a tuberculosis DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Protection against tuberculosis by a plasmid DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Prospects for a better vaccine against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Signal and propeptide processing of human tissue plasminogen activator: activity of a pro-tPA derivative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Current progress in tuberculosis vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Tuberculosis vaccine development: recent progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Fluorescence-based isolation of bacterial genes expressed within host cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

The influence of reduced oxygen availability on pathogenicity and gene expression in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Predicted highly expressed genes of diverse prokaryotic genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Genes required for mycobacterial growth defined by high density mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Role of the extracytoplasmic-function sigma factor sigma(H) in Mycobacterium tuberculosis global gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Vaccination against malaria: recent advances and the problems of antigenic diversity and other parasite evasion mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

A novel mechanism for Clostridium botulinum neurotoxin inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Zinc content of the Bacillus anthracis lethal factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Functional analysis of the Burkholderia cenocepacia ZmpA metalloprotease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Anthrax lethal factor inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

DNA vaccines against human immunodeficiency virus type 1 in the past decade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

Progress in DNA-based heterologous prime-boost immunization strategies for malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.025

10.1016/J.VACCINE.2006.05.025

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference